Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$100.95 USD

100.95
866,060

-0.01 (-0.01%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $100.94 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 245)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amedisys Ties Up With Medalogix to Boost Home Health Unit

by Zacks Equity Research

Amedisys (AMED) pursues deals to boost Home Health business.

    Zacks Equity Research

    Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for FYC

      Zacks Equity Research

      Why Is Amedisys (AMED) Up 18.5% Since Last Earnings Report?

      by Zacks Equity Research

      Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Awantika Poddar headshot

        6 Top Stock Options for Millennials Right Now

        by Awantika Poddar

        Millennials is the term generally applicable to individuals whose birth years ranges between 1981 and 1996

          Zacks Equity Research

          Zacks.com featured highlights include: Vitamin Shoppe, North American Construction, Verso, Amedisys and Heidrick & Struggles

          by Zacks Equity Research

          Zacks.com featured highlights include: Vitamin Shoppe, North American Construction, Verso, Amedisys and Heidrick & Struggles

            Sweta Killa headshot

            S&P 500 Tops 2,900: Best ETFs & Stocks of Best Sectors

            by Sweta Killa

            While nine of the S&P 500 sectors are performing well, information technology is leading the rally followed by consumer discretionary and healthcare.

              Nilanjan Choudhury headshot

              5 Stocks With Relative Price Strength to Boost Your Returns

              by Nilanjan Choudhury

              Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

                Awantika Poddar headshot

                5 Mid-Cap Stocks For Growth Investors to Buy Right Now

                by Awantika Poddar

                Investing in mid-cap companies is a safe bet, especially during economic downturns and stringent credit conditions.

                  Sweta Killa headshot

                  5 Growth Stocks at New Highs with Room for More Upside

                  by Sweta Killa

                  We have highlighted five growth stocks that hit all-time highs in the current market rally and will likely to continue to move higher given their superior fundamentals.

                    Zacks Equity Research

                    Here's Why You Should Add Amedisys (AMED) to Your Portfolio

                    by Zacks Equity Research

                    Amedisys (AMED) witnesses solid Medicare and non-Medicare revenues at Home Health and Hospice divisions. A favorable demographic trend bodes well.

                      Zacks Equity Research

                      Will Strong RTG Arm Shape Medtronic's (MDT) Q1 Earnings?

                      by Zacks Equity Research

                      Medtronic (MDT) poised to gain on continued growth in RTG business in Q1.

                        Zacks Equity Research

                        Will Solid Diabetes Arm Drive Medtronic's (MDT) Q1 Earnings?

                        by Zacks Equity Research

                        Medtronic (MDT) poised to gain on strength in Diabetes business in Q1 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.

                          Zacks Equity Research

                          Haemonetics Strong on Plasma Unit Amid Blood Center Weakness

                          by Zacks Equity Research

                          Haemonetics (HAE) witnesses strong growth in Plasma franchise. Dullness in Blood Center business prevails.

                            Zacks Equity Research

                            Hologic Launches Fluent Fluid Management System, Widens Suite

                            by Zacks Equity Research

                            Hologic (HOLX) adopts initiatives to boost the GYN Surgical segment.

                              Zacks Equity Research

                              Amedisys (AMED) Shares March Higher, Can It Continue?

                              by Zacks Equity Research

                              As of late, it has definitely been a great time to be an investor in Amedisys, Inc. (AMED).

                                Zacks Equity Research

                                Amedisys (AMED) Grows on Robust Home Health, Personal Care

                                by Zacks Equity Research

                                Amedisys' (AMED) solid performance in Personal Care division is impressive. Plus, a favorable demographic trend and calculating buyouts bode well for the company.

                                  Zacks Equity Research

                                  Here's Why You Should Invest in Align Technology (ALGN) Now

                                  by Zacks Equity Research

                                  We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally.

                                    Zacks Equity Research

                                    Medtronic Launches IN.PACT Admiral in Japan, Boosts APV Arm

                                    by Zacks Equity Research

                                    Medtronic's (MDT) recent launch of IN.PACT Admiral DCB in Japan is expected to boost the top line.

                                      Zacks Equity Research

                                      Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips

                                      by Zacks Equity Research

                                      At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues.

                                        Zacks Equity Research

                                        Hill-Rom (HRC) Q3 Earnings Top Estimates, Margins Expand

                                        by Zacks Equity Research

                                        Hill-Rom (HRC) registers a solid year-over-year revenue rise on strong domestic growth, driven by a robust performance at Patient Support Systems and Surgical Solutions.

                                          Zacks Equity Research

                                          Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Drop

                                          by Zacks Equity Research

                                          The improvement within Zimmer Biomet's (ZBH) global Knee and Hip sales performance and ongoing growth within the Asia Pacific region are encouraging.

                                            Zacks Equity Research

                                            GNC Holdings (GNC) Q2 Earnings Beat, Revenues Miss Mark

                                            by Zacks Equity Research

                                            Though GNC Holdings' (GNC) domestic retail comps are slightly weaker than expected, the company performs strongly in e-commerce business and at International segment.

                                              Zacks Equity Research

                                              Integra (IART) Reports In-Line Q2 Earnings, Tapers View

                                              by Zacks Equity Research

                                              Integra LifeSciences' (IART) balanced segmental revenue growth in Q2 is encouraging.

                                                Zacks Equity Research

                                                Align Technology (ALGN) Beats on Earnings and Revenues in Q2

                                                by Zacks Equity Research

                                                Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q2.

                                                  Zacks Equity Research

                                                  Chemed (CHE) Beats on Q2 Earnings & Revenues, View Raised

                                                  by Zacks Equity Research

                                                  Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q2.